Phase II study of tauromustine in disseminated malignant melanoma.
S B
SB
Gjedde
H T
HT
Mouridsen
E
E
L-Madsen
N V
NV
Jensen
E
E
Blomquist
J
J
Bergh
M
M
Söderberg
S
S
Wählby
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D013654:Taurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013654:Taurine; C052991:1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea